The rejected bid removes one possible buyer, but the committee cited regulatory risks and chose an amended HealthSpan deal. Its terms are not given, so the report does not clearly change Surgery Partners' outlook.
For Surgery Partners, losing this offer removes one possible path to a sale. The committee cited regulatory risks and possible closing delays, and the company chose a different merger agreement. The report gives no terms for the HealthSpan agreement, so it does not show whether that choice improves or weakens Surgery Partners' outlook.
UnitedHealth's $28-per-share offer was rejected, so it did not secure this deal. The report gives no effect on UnitedHealth's business, leaving its outlook unchanged by the information reported.
Follow Surgery Partners (SGRY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SGRY